NDAORALTABLET
Approved
Dec 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORETICYL 25 is a fixed-dose combination oral tablet containing deserpidine (a Rauwolfia alkaloid antihypertensive) and hydrochlorothiazide (a thiazide diuretic), approved in 1959 for hypertension management. This combination targets blood pressure reduction through dual mechanisms: sympathetic nervous system inhibition and sodium-water excretion. The product represents a legacy antihypertensive from the mid-20th century era.
LOE Approaching
Product faces imminent loss of exclusivity with minimal modern clinical support; team likely small and focused on maintenance rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect minimal career momentum; roles available are maintenance-focused rather than growth-oriented. Working on ORETICYL 25 offers limited skill development and weak market positioning for long-term career advancement.
Brand ManagerField Sales Representative
Worked on ORETICYL 25 at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.